J&J dumps Aegis Group's Carat

Share this article:
Johnson & Johnson dumped Aegis Group's Carat as it began a root-and-branch review of its media planning and buying assignments, according to Advertising Age. Carat had handled media on a number of the Pfizer OTC brands being acquired by J&J. Those brands will be divided up among roster agencies that survive the review, Ad Age reported.

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...